Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | RBP1 | P09455 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590267 | 0.81 | CNR1 (0.39) | CNR1CNR2HTR2AMAOAPTGDR2 | |
| SCHEMBL11704489 | 0.81 | CNR1 (0.42) | CNR1CNR2HTR2AMAOAHTT | |
| SCHEMBL3254797 | 0.79 | CNR1 (0.43) | CNR1CNR2HTR2ANPC1HPGD | |
| SCHEMBL9685845 | 0.78 | CNR1 (0.42) | CNR1CNR2HTR2AMAOANUDT1 | |
| SCHEMBL6231554 | 0.78 | NUDT1 (0.42) | CNR1CNR2NPC1HPGDMAPK1 | |
| SCHEMBL27534305 | 0.77 | CNR1 (0.43) | CNR1CNR2HTR2ANUDT1BACE1 | |
| SCHEMBL200174 | 0.75 | NUDT1 (0.45) | CNR1CNR2NPC1HPGDMAPK1 | |
| SCHEMBL10788064 | 0.75 | ALOX5 (0.44) | CNR1CNR2TYRALOX5 | |
| SCHEMBL27522087 | 0.74 | NUDT1 (0.46) | CNR1CNR2HTR2ANUDT1BACE1 | |
| SCHEMBL27480120 | 0.73 | NPC1 (0.44) | CNR1CNR2NPC1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CNR1 3323/4885CNR2 3732/4885HTR2A 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.